T Cell mediated Tumor Cell Lysis Assay Service

T cell-mediated tumor cell lysis represents a critical effector mechanism in adaptive antitumor immunity, enabling specific elimination of malignant cells through perforin-granzyme and death receptor pathways. Creative Biolabs' T Cell-mediated Tumor Cell Lysis Assay Service provides quantitative, reproducible analysis of cytotoxic activity for a wide range of effector and target cell systems, including patient-derived samples and engineered T cell products. This service delivers essential functional data to accelerate candidate selection, optimize therapeutic efficacy, and de-risk translation into preclinical and clinical applications.

Introduction

T cell-mediated tumor cell lysis is a process by which cytotoxic T lymphocytes (CTLs) identify and eliminate malignant cells through direct intercellular contact, primarily via the perforin-granzyme pathway and death receptor signaling. Understanding this mechanism is essential for evaluating adaptive antitumor immunity and for developing T cell-based immunotherapies, such as CAR-T and TCR-T therapies. Therefore, robust and quantitative T cell-mediated tumor cell lysis assays are of significant importance for assessing CTL efficacy, screening novel therapeutic agents, and predicting clinical responses in cancer immunotherapy.

Fig.1 Effector cell-mediated target cell killing mechanisms.¹

T Cell-mediated Tumor Cell Lysis Assay Service at Creative Biolabs

Creative Biolabs' T Cell-mediated Tumor Cell Lysis Assay Service leverages the antigen-specific cytolytic activity of engineered T cells against tumor cells to quantitatively assess their killing efficiency. Through rigorous and reproducible assays, we help accelerate the transition from research to clinical application by confirming the functional integrity and therapeutic potential of cell-based immunotherapies.

What we can offer

Our service offers a flexible and robust platform to support your immunotherapy development. We provide two distinct assay formats to accurately quantify T cell-induced tumor cell killing, enabling precise evaluation of cytotoxic efficacy in both research and preclinical settings.

Our Service Process

Required Starting Materials:

• Primary T cells, established T-cell lines, or genetically engineered T-cell products (such as CAR-T or TCR-T).
• Matched target tumor cell lines.
• Candidate immunomodulators or agonistic antibodies designated for evaluation.

Key Steps Involved:

Final Deliverables:

• Raw data files.
• A full technical report detailing the methodology, results, and conclusions.

Key Advantages

• Customized Assay Design: We partner with you to develop T-cell lysis assays aligned with your research objectives, incorporating your selected effector cells, target cells, and immunomodulatory agents.
• Diverse Assay Platforms: Our services encompass multiple detection formats, including high-throughput systems and highly reproducible bioluminescence or impedance-based methodologies.
• Flexible Cell Selection: Assays can be configured using your supplied T-cell lines or engineered products, along with an extensive array of tumor target cells, including custom or patient-derived lines.

FAQ

Why Choose Us?

Creative Biolabs has built a strong reputation in the field, backed by extensive expertise and a steadfast commitment to high-quality scientific outcomes. Our robust assay systems are founded on well-established experimental protocols and cutting-edge technologies, ensuring both reliability and high translational value of the data.

Customer Reviews

"Employing Creative Biolabs' T Cell-mediated Tumor Cell Lysis Assay Service greatly accelerated our screening workflow and enhanced the reproducibility of our results. Their high-throughput platform enabled rapid evaluation of hundreds of candidate cells, while consistently delivering data of exceptional quality." Jn De.

"The lytic activity data proved critical in confirming the efficacy of our lead T-cell construct. Creative Biolabs provided expert technical support to optimize a challenging co-culture system, ultimately demonstrating the significant cytotoxic enhancement we aimed to achieve. The comprehensive report contained all necessary details for our regulatory filing." Aa Rs.

"After encountering considerable variability with in-house assays, we transitioned to Creative Biolabs for their standardized procedures and precise execution. Their ability to incorporate a custom cell line seamlessly addressed our specific project needs, yielding reliable and consistent data that bolstered our confidence in the outcomes." Cs Mr.

Related Services

Building upon extensive research expertise in CAR technology, Creative Biolabs offers an integrated One-Stop CAR-T Therapy Development service. This end-to-end solution spans from CAR design and construction to comprehensive in vitro and in vivo functional validation of CAR-T products. For research and development support in this advancing field, we invite you to connect with our specialist team. Our scientists are readily available to assist with your project requirements.

How to contact us?

At Creative Biolabs, we are committed to driving progress in T-cell immunotherapy through the delivery of cutting-edge research tools and specialized services. Our team of experts is ready to support your innovative projects—contact us today to discover how our solutions can accelerate your next discovery.

Reference

1. Tuomela, Karoliina et al. "Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity." Frontiers in immunology vol. 13 867098. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2022.867098.